271 related articles for article (PubMed ID: 35989498)
1. Celastrol: A lead compound that inhibits SARS-CoV-2 replication, the activity of viral and human cysteine proteases, and virus-induced IL-6 secretion.
Fuzo CA; Martins RB; Fraga-Silva TFC; Amstalden MK; Canassa De Leo T; Souza JP; Lima TM; Faccioli LH; Okamoto DN; Juliano MA; França SC; Juliano L; Bonato VLD; Arruda E; Dias-Baruffi M
Drug Dev Res; 2022 Nov; 83(7):1623-1640. PubMed ID: 35989498
[TBL] [Abstract][Full Text] [Related]
2. Olive-Derived Triterpenes Suppress SARS COV-2 Main Protease: A Promising Scaffold for Future Therapeutics.
Alhadrami HA; Sayed AM; Sharif AM; Azhar EI; Rateb ME
Molecules; 2021 May; 26(9):. PubMed ID: 34062737
[TBL] [Abstract][Full Text] [Related]
3. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.
Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC
J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646
[TBL] [Abstract][Full Text] [Related]
4. Interrelated Mechanism by Which the Methide Quinone Celastrol, Obtained from the Roots of
Caruso F; Singh M; Belli S; Berinato M; Rossi M
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291769
[TBL] [Abstract][Full Text] [Related]
5. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
Fintelman-Rodrigues N; Sacramento CQ; Ribeiro Lima C; Souza da Silva F; Ferreira AC; Mattos M; de Freitas CS; Cardoso Soares V; da Silva Gomes Dias S; Temerozo JR; Miranda MD; Matos AR; Bozza FA; Carels N; Alves CR; Siqueira MM; Bozza PT; Souza TML
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32759267
[TBL] [Abstract][Full Text] [Related]
6.
Umadevi P; Manivannan S; Fayad AM; Shelvy S
J Biomol Struct Dyn; 2022 Jul; 40(11):5053-5059. PubMed ID: 33372574
[No Abstract] [Full Text] [Related]
7. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
[TBL] [Abstract][Full Text] [Related]
8. Dual Inhibitors of Main Protease (M
Mondal S; Chen Y; Lockbaum GJ; Sen S; Chaudhuri S; Reyes AC; Lee JM; Kaur AN; Sultana N; Cameron MD; Shaffer SA; Schiffer CA; Fitzgerald KA; Thompson PR
J Am Chem Soc; 2022 Nov; 144(46):21035-21045. PubMed ID: 36356199
[TBL] [Abstract][Full Text] [Related]
9. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.
Anirudhan V; Lee H; Cheng H; Cooper L; Rong L
J Med Virol; 2021 May; 93(5):2722-2734. PubMed ID: 33475167
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
Huff S; Kummetha IR; Tiwari SK; Huante MB; Clark AE; Wang S; Bray W; Smith D; Carlin AF; Endsley M; Rana TM
J Med Chem; 2022 Feb; 65(4):2866-2879. PubMed ID: 34570513
[TBL] [Abstract][Full Text] [Related]
11. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
12. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
J A; Francis D; C S S; K G A; C S; Variyar EJ
J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
[TBL] [Abstract][Full Text] [Related]
13. Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS-COV-2 targeting main protease and papain-like protease.
Choudhary S; Nehul S; Singh A; Panda PK; Kumar P; Sharma GK; Tomar S
IUBMB Life; 2024 May; 76(5):228-241. PubMed ID: 38059400
[TBL] [Abstract][Full Text] [Related]
14. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
Molecules; 2020 May; 25(11):. PubMed ID: 32485894
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
16. High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors.
Zang Y; Su M; Wang Q; Cheng X; Zhang W; Zhao Y; Chen T; Jiang Y; Shen Q; Du J; Tan Q; Wang P; Gao L; Jin Z; Zhang M; Li C; Zhu Y; Feng B; Tang B; Xie H; Wang MW; Zheng M; Pan X; Yang H; Xu Y; Wu B; Zhang L; Rao Z; Yang X; Jiang H; Xiao G; Zhao Q; Li J
Protein Cell; 2023 Jan; 14(1):17-27. PubMed ID: 36726755
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking and simulation studies of natural compounds of
Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
[TBL] [Abstract][Full Text] [Related]
18. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
[TBL] [Abstract][Full Text] [Related]
19. Effect of dihydromyricetin on SARS-CoV-2 viral replication and pulmonary inflammation and fibrosis.
Xiao T; Wei Y; Cui M; Li X; Ruan H; Zhang L; Bao J; Ren S; Gao D; Wang M; Sun R; Li M; Lin J; Li D; Yang C; Zhou H
Phytomedicine; 2021 Oct; 91():153704. PubMed ID: 34419736
[TBL] [Abstract][Full Text] [Related]
20. Ciclesonide Inhibits SARS-CoV-2 Papain-Like Protease in Vitro.
Kiba Y; Tanikawa T; Kitamura M
Biol Pharm Bull; 2024; 47(5):965-966. PubMed ID: 38763750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]